Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2024-04-03 00:00:00 ET · period of report 2024-04-01 · accession 0001601830-24-000029 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-04-03 | 2024-04-01 | RXRX | Dar Zavain | Dir | A - Grant | $0.00 | +1,467 | 89.1K | +2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2024-04-01 | A | A | 1,467 | $0.00 | 89,056 | D | — | — | (F1) Shares were issued pursuant to the Issuer's Outside Director Compensation Policy. (F2) Includes a total of 32,373 shares received pursuant to a pro-rata distribution from Lux Ventures, of which the Reporting Person was a limited partner. The acquisition of such shares was exempt pursuant to Rule 16a-9 and was inadvertently excluded from the total amount of shares held on the Reporting Person's Forms 4 since July 12, 2023. |